Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIMP3 | P35625 | 6/20 | 1.00 |
| ▸ | RECQL | P46063 | 5/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | USP2 | O75604 | 2/20 | 0.76 |
| ▸ | F11 | P03951 | 2/20 | 0.69 |
| ▸ | HPSE | Q9Y251 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | PKM | P14618 | 4/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.68 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 4/20 | 0.68 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.68 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.68 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.68 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.68 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18136599 | 0.96 | TIMP3 (0.93) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL16255254 | 0.91 | P2RY11 (0.84) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL16453923 | 0.89 | TIMP3 (0.80) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL11426011 | 0.87 | TIMP3 (0.77) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL11487866 | 0.86 | TIMP3 (0.76) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL30392305 | 0.86 | RECQL (1.00) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL3358966 | 0.86 | RECQL (1.00) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL375680 | 0.85 | TIMP3 (0.75) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL11435939 | 0.85 | TIMP3 (0.74) | TIMP3RECQLKMT2AHSD17B10TDP1 | |
| SCHEMBL10897758 | 0.85 | TIMP3 (0.73) | TIMP3RECQLKMT2AHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | claimed |
| US-20150057331-A1 | NOVEL CELLULAR TARGETS FOR HIV INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-02-26 | — | — | US | claimed |
| US-20140123342-A1 | Regulation of Stomatal Apertures by Apyrases and Extracellular Nucleotides | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-01 | — | — | US | claimed |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | US | claimed |
| US-8399018-B2 | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-03-19 | — | — | US | claimed |
| WO-2012167023-A2 | REGULATION OF STOMATAL APERTURES BY APYRASES AND EXTRACELLULAR NUCLEOTIDES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-06 | — | — | WO | claimed |
| US-20040029841-A1 | Purinergic antagonists for treating depression | MCLEAN HOSPITAL CORPORATION, THE | 2004-02-12 | — | — | US | claimed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-2867368-B1 | SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER | ROUSSY INST GUSTAVE (FR) | 2022-01-12 | — | — | EP | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20110065675-A1 | AZO DYE RELATED SMALL MOLECULE MODULATORS OF PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF MIAMI (US) | 2011-03-17 | — | — | US | disclosed |
| US-20100015228-A1 | CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009137471-A2 | AZO DYE RELATED SMALL MOLECULE MODULATORS OF PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF MIAMI (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20070099863-A1 | Compounds for the treatment of demyelinating and autoimmune diseases | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO (ES) | 2007-05-03 | — | — | US | disclosed |
| US-20040029841-A1 | Purinergic antagonists for treating depression | MCLEAN HOSPITAL CORPORATION, THE | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065675-A1 | AZO DYE RELATED SMALL MOLECULE MODULATORS OF PROTEIN-PROTEIN INTERACTIONS | CD74, CD4, CD2 | TIMP3 4337/4885RECQL 1487/4885KMT2A 4711/4885 |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | TRPV1, ATP2A1, TRPM2 | TIMP3 2109/4885RECQL 479/4885KMT2A 3763/4885 |
| US-20100015228-A1 | CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | TRPV1, ATP2A1, TRPM2 | TIMP3 2109/4885RECQL 479/4885KMT2A 3763/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | TIMP3 555/4885RECQL 644/4885KMT2A 3055/4885 |
| US-20070099863-A1 | Compounds for the treatment of demyelinating and autoimmune diseases | P2RX2, P2RX3, P2RX1 | TIMP3 3417/4885RECQL 902/4885KMT2A 3058/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | TIMP3 776/4885RECQL 1250/4885KMT2A 3984/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | TIMP3 776/4885RECQL 1250/4885KMT2A 3984/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | TIMP3 776/4885RECQL 1250/4885KMT2A 3984/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | TIMP3 1503/4885RECQL 1042/4885KMT2A 3482/4885 |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | TIMP3 1422/4885RECQL 92/4885KMT2A 2312/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | TIMP3 776/4885RECQL 1250/4885KMT2A 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.